Goodman Cancer Centre and Department of Biochemistry
Tommy Alain has not added Biography.
If you are Tommy Alain and would like to personalize this page please email our Author Liaison for assistance.
Oncolytic reovirus against ovarian and colon cancer.
Cancer research Mar, 2002 | Pubmed ID: 11912142
Reovirus therapy of lymphoid malignancies.
Blood Dec, 2002 | Pubmed ID: 12393565
Lymphomas and oncolytic virus therapy.
Clinical lymphoma Sep, 2003 | Pubmed ID: 14556682
Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo.
Journal of immunology (Baltimore, Md. : 1950) Sep, 2004 | Pubmed ID: 15356104
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Cancer research Nov, 2005 | Pubmed ID: 16267023
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Journal of the National Cancer Institute Nov, 2006 | Pubmed ID: 17077357
Proteolytic disassembly is a critical determinant for reovirus oncolysis.
Molecular therapy : the journal of the American Society of Gene Therapy Aug, 2007 | Pubmed ID: 17519890
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.
Cancer research Sep, 2007 | Pubmed ID: 17875723
Susceptibility of mantle cell lymphomas to reovirus oncolysis.
Leukemia research Jan, 2010 | Pubmed ID: 19651440
Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.
Molecular oncology Dec, 2009 | Pubmed ID: 19766068
p53-dependent translational control of senescence and transformation via 4E-BPs.
Cancer cell Nov, 2009 | Pubmed ID: 19878875
The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America Dec, 2009 | Pubmed ID: 20018725
Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Cancer research Jan, 2010 | Pubmed ID: 20068158
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.
Proceedings of the National Academy of Sciences of the United States of America Jan, 2010 | Pubmed ID: 20080710
Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing.
Nucleic acids research Jul, 2010 | Pubmed ID: 20413581
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs.
Science (New York, N.Y.) May, 2010 | Pubmed ID: 20508131
Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters.
The Journal of biological chemistry Aug, 2011 | Pubmed ID: 21659537
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.
Cancer cell Oct, 2011 | Pubmed ID: 22014571
IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
Journal of immunology (Baltimore, Md. : 1950) May, 2012 | Pubmed ID: 22447977
Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.
The Journal of biological chemistry May, 2012 | Pubmed ID: 22474287
Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E.
Nature immunology Jun, 2012 | Pubmed ID: 22544393
Distinct perturbation of the translatome by the antidiabetic drug metformin.
Proceedings of the National Academy of Sciences of the United States of America Jun, 2012 | Pubmed ID: 22611195
A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development.
Molecular and cellular biology Sep, 2012 | Pubmed ID: 22751931
eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Cancer research Dec, 2012 | Pubmed ID: 23100465
mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.
Oncotarget Dec, 2012 | Pubmed ID: 23455427
Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex.
Molecular and cellular biology Jul, 2013 | Pubmed ID: 23608534
Control of translation and miRNA-dependent repression by a novel poly(A) binding protein, hnRNP-Q.
PLoS biology , 2013 | Pubmed ID: 23700384
Translational control of entrainment and synchrony of the suprachiasmatic circadian clock by mTOR/4E-BP1 signaling.
Neuron Aug, 2013 | Pubmed ID: 23972597
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.
Cell metabolism Nov, 2013 | Pubmed ID: 24206664
Control of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinase.
Molecular and cellular biology Mar, 2014 | Pubmed ID: 24396066
Multifaceted regulation of somatic cell reprogramming by mRNA translational control.
Cell stem cell May, 2014 | Pubmed ID: 24630793
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved